The EIF4A2 Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population generated from the HGC-27 human gastric adenocarcinoma cell line. This product provides a heterogeneous pool of cells with targeted disruption of the EIF4A2 gene, enabling pooled loss-of-function studies while avoiding clonal artifacts. It is designed for investigating EIF4A2-dependent translation regulatory mechanisms and functional genomics in tumor biology.
HGC-27 is an epithelial cell line derived from the metastatic lymph node of a gastric cancer patient, widely used as a model for gastric adenocarcinoma. These cells display characteristic features of gastric cancer, including dysregulated growth signaling and oncogenic translation, making them an appropriate host for dissecting translational control in gastrointestinal malignancy.
EIF4A2 encodes a DEAD-box RNA helicase that is a catalytic subunit of the eIF4F complex, where it interacts with eIF4E and eIF4G to unwind mRNA 5′ UTR secondary structures during cap-dependent translation initiation. Its activity is positively regulated by mTORC1 downstream of PI3K-AKT signaling in response to growth factors and nutrients, and is inhibited by the tumor suppressor PDCD4. EIF4A2 cooperates with eIF4B and eIF4H to enhance helicase processivity, driving the translation of pro-proliferative and pro-survival proteins. Aberrant mTORC1-mediated activation of eIF4F contributes to oncogenic translation in multiple cancers.
In gastric cancer, overexpression of EIF4A2 is associated with enhanced protein synthesis and tumor progression. The knockout of EIF4A2 in HGC-27 cells creates a valuable isogenic model to examine its role in maintaining the oncogenic translation program, cell proliferation, and apoptosis resistance. This system allows investigation of EIF4A2 as a potential therapeutic target in gastric adenocarcinoma and its involvement in the translation of specific oncogenic drivers.
The EIF4A2 Knockout HGC-27 Polyclonal Cells are suited for diverse applications, including target validation studies with eIF4A inhibitors, mechanistic dissection of translation initiation, and synthetic lethality screens. Representative downstream assays include western blotting for pathway components, RT-qPCR and RNA-seq for transcription and translation analyses, polysome profiling to assess ribosome occupancy, and luciferase reporters with structured 5’UTRs to measure helicase activity. Co-immunoprecipitation can confirm interactions with eIF4E, eIF4G, and PDCD4. For additional information, please contact Ascent Research.
